



Vosko, Milan R., et al. „C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke.“ International Journal of Stroke 20.9 (2025): 1060-1070.

TBI

STROKE


COGNITIVE DISORDERS

Positive mRS data at day 90 with Cerebrolysin Confirmed in a large-scale clinical trial

Mann-Whitney Statistic (MW)

mRS Day 90 – primary endpoint
Wei-Lachin

MW	95,00%-CI	N1/N2	P
0,6157	(0,5910 to 0,6404)	969/726	0,0000



mRS at 90 days after stroke onset, MW effect size

Significant superiority with Cerebrolysin achieved!


Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Twice as many patients achieving **EXCELLENT OUTCOME** (mRS 0-1) with Cerebrolysin


Cerebrolysin group

Number of patients with excellent outcome
45 per 100 patients treated with Cerebrolysin



Control group

Number of patients with excellent outcome
20 per 100 patients treated with standard therapy



What does an **EXCELLENT OUTCOME** mean for the patient?

mRS	Symptoms	Independence	Typical Patient Description
0	No symptoms at all	<p>Fully independent</p>	<ul style="list-style-type: none"> No symptoms at all Can do everything exactly as before the stroke Walks normally, speaks normally, is fully independent Looks completely healthy, no signs of impairment
1	No significant disability despite symptoms		<ul style="list-style-type: none"> Minor symptoms; no impact on daily activities, fully independent Can work, drive, care for themselves without help

Start Cerebrolysin treatment from **DAY 1**

Disorder	Daily dosage	Initiation of treatment	Duration of treatment
Stroke	30 ml	as soon as possible ideally from day 1	21 days

Cerebrolysin is safe and well tolerated.

As recommended in different guidelines

Copyright © 2026 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorization Holder: EVER Neuro Pharma GmbH, A-4866 Unterach Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC-CCDS Version 2.0/03.06.2016)